title: Recent findings in asthma likely to impact patient care.
abstract: The management of asthma is becoming increasingly complex as more pharmacologic agents become available and we gain increased understanding of the pathogenetic processes of asthma and the risks for potentially irreversible airway remodeling that might be increased by suboptimal management and interactions with concomitant disease states such as gastroesophageal reflux. Although physicians now have greater responsibility to make use of this increasing knowledge to provide more effective management for their asthma patients, they also have a greater opportunity to increase the overall quality of life of patients under their care.
authors.affiliation: Department of Internal Medicine, Saint Louis University School of Medicine, Missouri 63104, USA.
authors.forename: M S
authors.initials: MS
authors.lastname: Dykewicz
authors.forename: D K
authors.initials: DK
authors.lastname: Ledford
mesh_terms: D000318:Adrenergic beta-Agonists / Q000627:therapeutic use; D000420:Albuterol / Q000031:analogs & derivatives / Q000627:therapeutic use; D018927:Anti-Asthmatic Agents / Q000627:therapeutic use*; D001249:Asthma / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy* / Q000276:immunology; D005764:Gastroesophageal Reflux / Q000150:complications; D006801:Humans; D007211:Indoles; D007249:Inflammation; D020024:Leukotriene Antagonists; D048448:Phenylcarbamates; D000068299:Salmeterol Xinafoate; D013449:Sulfonamides; D014105:Tosyl Compounds / Q000627:therapeutic use
chemical_list: D000318:Adrenergic beta-Agonists; D018927:Anti-Asthmatic Agents; D007211:Indoles; D020024:Leukotriene Antagonists; D048448:Phenylcarbamates; D013449:Sulfonamides; D014105:Tosyl Compounds; D000068299:Salmeterol Xinafoate; D000420:Albuterol; C062735:zafirlukast